scholarly journals COVID-19 and cardiovascular complications – the preliminary results of the LATE-COVID study

Author(s):  
Joanna Lewek ◽  
Izabela Jatczak-Pawlik ◽  
Marek Maciejewski ◽  
Piotr Jankowski ◽  
Maciej Banach

IntroductionCoronavirus Disease 2019 (COVID-19) may affect many organs and may be responsible for numerous complications including cardiovascular problems.Material and methodsWe analysed consecutive patients (n=51) admitted to the cardiology department between 1st October 2020 and 31st January 2021 due to symptoms, which might have reflected cardiovascular complications following COVID-19.ResultsThe complications after Covid-19 appeared after 1-4 months after disease recovery.ConclusionsDiabetes, elevated level of CRP and troponin, heart rate variability parameters and worsening of left ventricular ejection fraction are related to the severity of cardiovascular complications following the COVID-19 infection.

2021 ◽  
Author(s):  
Mohanad Alkhodari ◽  
Herbert F. Jelinek ◽  
Shiza Saleem ◽  
Leontios J. Hadjileontiadis ◽  
Ahsan H. Khandoker

Abstract Analysis of heart failure is important in clinical practice to ensure coronary artery disease (CAD) patients will be provided with appropriate timely treatment. The current gold standard, echocardiography, although reliable, provides a once-off left ventricular ejection fraction (LVEF) measurement but does not provide information about heart function the during day / night cardiac cycles. The aim of this study was to investigate the ability of heart rate variability (HRV) features in classifying CAD patients into multiple LVEF groups through a new index, HRV ejection fraction (HRVEF) and its agreement to established norms. A total of 92 heart failure patients were included in this study. HRVEF groups optimized on hourly basis through Jenks natural breaks algorithm exhibited a consistent pattern with a goodness of variance fit (GVF) of more than 0.70 accuracy during the late-night to early-morning (01:00-08:00) and evening (17:00-23:00) time periods. At these hours, several HRV features were found significant in differentiating between HRVEF groups using statistical analysis of variance (ANOVA) test. These features include the successive differences between normal heartbeats (RMSSD), low and high frequency (LF, HF) power, standard deviation of normal heartbeats (SD2), short-term scaling exponent (alpha1), and percentage of normal heartbeats in alternation segments (PAS). This study paves the way towards new LVEF guidelines based on the association between LVEF and HRV features for a better demonstration of the circadian cardiac function at different LVEF levels in CAD patients.


2016 ◽  
Vol 5 (1) ◽  
pp. 31 ◽  
Author(s):  
Konstantinos D Rizas ◽  
◽  
Wolfgang Hamm ◽  
Stefan Kääb ◽  
Georg Schmidt ◽  
...  

Periodic repolarisation dynamics (PRD) refers to low-frequency (≤0.1Hz) modulations of cardiac repolarisation instability. Spontaneous PRD can be assessed non-invasively from 3D high-resolution resting ECGs. Physiological and experimental studies have indicated that PRD correlates with efferent sympathetic nerve activity, which clusters in low-frequency bursts. PRD is increased by physiological provocations that lead to an enhancement of sympathetic activity, whereas it is suppressed by pharmacological b-blockade. Electrophysiological studies revealed that PRD occurs independently from heart rate variability. Increased PRD under resting conditions is a strong predictor of mortality in post-myocardial infarction (post-MI) patients, yielding independent prognostic value from left-ventricular ejection fraction (LVEF), heart rate variability, the Global Registry of Acute Coronary Events score and other established risk markers. The predictive value of PRD is particularly strong in post-MI patients with preserved LVEF (>35 %) in whom it identifies a new high-risk group of patients. The upcoming Implantable Cardiac Monitors in High-Risk Post-Infarction Patients with Cardiac Autonomic Dysfunction and Moderately Reduced Left Ventricular Ejection Fraction (SMART-MI) trial will test prophylactic strategies in high-risk post-MI patients with LVEF 36–50 % identified by PRD and deceleration capacity of heart rate (NCT02594488).


Sign in / Sign up

Export Citation Format

Share Document